



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/853,080	05/09/2001	Ruth Laub	VANMA48.001CP1	5269
20995	7590 03/10/2004		EXAM	INER
	MARTENS OLSON & BI	NOLAN, PATRICK J		
2040 MAIN STREET FOURTEENTH FLOOR			ART UNIT	PAPER NUMBER
IRVINE, CA 92614			1644	 -
	•		DATE MAILED: 03/10/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

A
1,
S

Office Action Summary

Application No.	Applicant(s)	
09/853,080	LAUB ET AL.	
Examiner	Art Unit	
Patrick J. Nolan	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -- Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE $\underline{1}$ MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.

 after SIX (b) MONTHS from the maining date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the If NO period for reply is specified above, the maximum statutory period will apply a Failure to reply within the set or extended period for reply will, by statute, cause th Any reply received by the Office later than three months after the mailing date of the earned patent term adjustment. See 37 CFR 1.704(b). 	and will expire SIX (6) MONTHS from the mailing date of this communication. e application to become ABANDONED (35 U.S.C. § 133)					
Status						
1) Responsive to communication(s) filed on <u>05 December</u>	<u>ər 2003.</u>					
2a) This action is FINAL . 2b) This action	is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte	Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 29-41 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 29-41 are subject to restriction and/or election	n requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority	under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5)					

- 1. Claims 1-28 have been cancelled. Newly added claims 29-41 are pending.
- 2. Applicant's election without traverse of Group I claims 1-15 and 20-23 in the Paper received 12-5-2003 is acknowledged.
- 3. Upon further consideration, the following restriction requirement is required between the newly submitted claims.
- 4. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 29-30 and 34-38, drawn to polypeptide from domain C of Factor VIII, classified in class 530, subclass 300.
 - II. Claims 31-33 and 39-41, drawn to a device with a polypeptide from domain C of Factor VIII, classified in class 435, subclass 283.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately usable. In the instant case, invention I has separate utility such as treatment methods or antibody generation. See MPEP § 806.05(d).

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

- 5. It is noted that if applicant elects the peptide alone product claim, once the peptide claims become allowable, if applicant amends the device claims to depend from the allowed product claims, the device claims will be rejoined.
- 6. The fax number for the organization where this application or proceeding is assigned is 703-872-9306.
- 7. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is 571-272-0847.
- 9. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at 571-272-0841.

Patrick J. Nolan, Ph.D.

fax INOC

Primary Examiner, Group 1640

March 8, 2004